Drug Trial Radar · NCT06674694
The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Apr 10, 2024
Primary completion
Jun 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Sichuan Kelun Pharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects/patients with schizophrenia.
Conditions
- Schizophrenia Disorders
Interventions
Brexpiprazole long-acting injectionDrug
A single injection was administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of reported Adverse Events (AE)Time frame: Collected from signing of informed consent until 90 days after a single dose.
- Clinical Laboratory TestsTime frame: Collected from signing of informed consent until 90 days after a single dose.
- Change in physical exam resultsTime frame: Collected from signing of informed consent until 90 days after a single dose.
- Vital signsTime frame: Collected from signing of informed consent until 90 days after a single dose.
- ECG ReadingTime frame: Collected from signing of informed consent until 90 days after a single dose.
- Extrapyramidal Symptoms (EPS) Rating ScaleTime frame: Collected from signing of informed consent until 90 days after a single dose.
- Change in Suicidality via Columbia-Suicide Severity Rating ScaleTime frame: Collected from signing of informed consent until 90 days after a single dose.
- Injection site assessmentTime frame: Collected from signing of informed consent until 90 days after a single dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anding Hospital Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.